6-硝基-1H-吲唑-3-甲醇 | 1000341-10-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 中文名称: 6-硝基-1H-吲唑-3-甲醇
• 英文名称: (6-Nitro-1H-indazol-3-yl)methanol
• 英文别名: (6-nitro-2H-indazol-3-yl)methanol
• CAS: 1000341-10-5
• 化学式: C8H7N3O3
• 分子量: 193.16
• InChiKey: IBUYUAQQNOCNJJ-UHFFFAOYSA-N

物化性质

• 沸点：
  483.6±30.0 °C(Predicted)
• 密度：
  1.599

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  94.7
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors
  申请人：Schering Aktiengesellschaft

  公开号：EP1657241A1

  公开（公告）日：2006-05-17

  The invention relates to novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis.

  这项发明涉及新型蒽酰胺吡啶脲作为VEGF受体激酶抑制剂，它们的生产和用作治疗由持续血管生成引发的疾病的药物代理。
• Anthranilamide pyridinureas as VEGF receptor kinase inhibitors
  申请人：Schering Aktiengesellschaft

  公开号：EP1655295A1

  公开（公告）日：2006-05-10

  The invention relates to novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis.

  本发明涉及一种新型的蒽酰胺吡啶脲作为VEGF受体激酶抑制剂，其制备和用作药物治疗由持续血管生成引起的疾病。
• Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
  申请人：Schering Aktiengesellschaft

  公开号：EP1655297A1

  公开（公告）日：2006-05-10

  The invention relates to novel nicotinamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis.

  本发明涉及一种新型的烟酰胺吡啶脲类VEGF受体激酶抑制剂，其生产和用作药物治疗由持续血管生成引起的疾病。
• Novel anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
  申请人：Bohlmann Rolf

  公开号：US20060116380A1

  公开（公告）日：2006-06-01

  The invention relates to novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for preventing or treating diseases that are triggered by persistent angiogenesis.

  本发明涉及一种新型的蒽酰胺吡啶脲作为VEGF受体激酶抑制剂，它们的制备和用作药物代理，用于预防或治疗由持续血管生成引起的疾病。
• Novel nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
  申请人：Bohlmann Rolf

  公开号：US20060160861A1

  公开（公告）日：2006-07-20

  The invention relates to novel nicotinamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for preventing or treating diseases that are triggered by persistent angiogenesis.

  本发明涉及一种新型烟酰胺吡啶脲作为VEGF受体激酶抑制剂，它们的制备方法以及作为预防或治疗由持续性血管生成引起的疾病的药物代理的用途。